A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease "ARRIVE"


Phase 3 Results

Summary of Purpose

The use of acetylsalicylic acid in the primary prevention of cardiovascular events has been extensively studied. However, the overall risk level of the study populations was low (< 10% 10-year CHD risk). The current study is designed to prove the efficacy and tolerability of 100 mg enteric-coated Aspirin versus placebo in the prevention of cardiovascular disease (CVD) events, which include fatal and nonfatal...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 19 September 2017.

5 Jul 2007 12 Jul 2007 15 Nov 2016 15 Nov 2016 1 Sep 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
  • Purpose: Prevention
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment


  • Bayer Clinical Trials Contact Tony Johns tony.johns.b@bayer.com Phone: 973-254-4675 2nd email contact: james.angello.b@bayer.com